Exchange Traded Concepts’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Exchange Traded Concepts’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-23,209	Closed	-$366K	–	1436
2023 Q3	$366K	Buy	+23,209	New	+$417K	0.01%	712
2023 Q1	–	Sell	-33,257	Closed	-$972K	–	1308
2022 Q4	$972K	Buy	33,257 +1,012	+3%	+$32.2K	0.03%	314
2022 Q3	$852K	Buy	32,245 +1,499	+5%	+$55K	0.03%	300
2022 Q2	$1.37M	Buy	30,746 +912	+3%	+$41.9K	0.04%	232
2022 Q1	$1.48M	Buy	+29,834	New	+$1.43M	0.03%	261
2021 Q3	–	Sell	-22,897	Closed	-$980K	–	1273
2021 Q2	$980K	Buy	22,897 +2,170	+10%	+$89.5K	0.03%	329
2021 Q1	$865K	Buy	20,727 +6,573	+46%	+$305K	0.03%	314
2020 Q4	$659K	Buy	14,154 +1,368	+11%	+$64K	0.03%	294
2020 Q3	$543K	Buy	12,786 +7,113	+125%	+$311K	0.03%	284
2020 Q2	$272K	Buy	+5,673	New	+$283K	0.05%	412

Other funds holding EGRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Exchange Traded Concepts's EGRX Position: Q4 2023 in Review

Exchange Traded Concepts sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2023, closing a stake of 23,209 shares — an estimated $366K sold.

Exchange Traded Concepts first reported a position in EGRX in Q2 2020 and held it in 10 quarters. The position peaked at $1.48M in Q1 2022. 104 funds tracked by Wall St. Rank hold EGRX as of Q4 2023.

Exchange Traded Concepts reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
Exchange Traded Concepts sold 23,209 Eagle Pharmaceuticals, Inc. shares in Q4 2023, an estimated $366K.
Exchange Traded Concepts first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2020 and held it in 10 quarters.
Exchange Traded Concepts's Eagle Pharmaceuticals, Inc. position peaked at $1.48M in Q1 2022.
104 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2023.

Based on Exchange Traded Concepts's 13F filing for Q4 2023, filed 5 Jan 2024.